- Patents registered for 'PD-L1 바카라 사이트 technology' and 'PD-L1 and CD47 dual 바카라 사이트 technology'
- Dual antibody with simplified structure through single-chain formulation
[by Ji, Yong Jun] Shaperon announced on August 12 that it has registered two key patents for its next-generation dual-antibody immunotherapy technology, developed using its ‘NanoMab’ platform.
The newly registered patents are for ‘NanoMab technology targeting PD-L1’ and ‘Dual NanoMab technology targeting PD-L1 and CD47.’ With these registrations, 바카라 사이트 has secured exclusive rights to original technology capable of simultaneously blocking the immune evasion mechanisms of two different cancers. According to the company, this represents the world's first dual-antibody technology based on NanoMab, anticipated to improve both therapeutic efficacy and safety in the immuno-oncology market.
PD-L1 and CD47 are key molecules that inhibit the anti-cancer immune functions of the human body's ‘adaptive immune cells (T lymphocytes)’ and ‘innate immune cells (macrophages),’ respectively. The company stressed that there is substantial unmet global demand for therapies capable of simultaneously inhibiting dual targets, particularly in triple-negative breast cancer, non-small cell lung cancer, and acute myeloid leukemia. When both molecules are expressed concurrently, patient prognosis is extremely poor, and the effectiveness of existing treatments is significantly limited.
Papiliximab, 바카라 사이트’s dual NanoMab antibody drug candidate currently in development, has demonstrated a significant reduction in tumor size in animal models. The company noted that it also overcame the side effects that had previously stalled the clinical development of PD-L1/CD47 bispecific antibody drug candidates from multinational pharmaceutical firms. Specifically, the company added that ‘anemia caused by red blood cell hemolysis,’ a side effect observed with competing CD47-targeting antibody treatments, was not detected in monkey studies administered with papiliximab, raising high expectations for its clinical potential.
The global market for dual antibody immunotherapy is projected to reach KRW 13 trillion (approximately USD 9.3 billion) this year, with an average annual growth rate exceeding 18%. While over 200 single-target, conventional antibody therapies have been commercialized, only about 20 conventional bispecific antibody therapies are currently available. This disparity stems from technical limitations in developing bispecific antibodies using a four-chain complex structure, including issues of structural heterogeneity, production safety, and impurity control.
바카라 사이트's papiliximab is built on a nanobody (NanoMab) platform that reduces the size of conventional antibodies to one-tenth that of existing antibodies. Although it is a bispecific antibody, it can be designed as a single-chain antibody, yielding a simplified structure. 바카라 사이트 highlighted that this approach has dramatically improved manufacturing efficiency and quality stability while also substantially lowering the risk of unwanted immune responses and side effects.
"These patents cover an innovative treatment capable of simultaneously addressing the limitations of existing bispecific antibodies in terms of therapeutic efficacy and the anemia side effect," a 바카라 사이트 official stated. "As we expand our global patent portfolio, discussions regarding early commercialization are expected to become more tangible."